As­traZeneca en­ters pre­clin­i­cal cell ther­a­py deal with Cana­di­an biotech

Cana­di­an cell ther­a­py biotech Ser­no­va an­nounced a pre­clin­i­cal re­search deal with As­traZeneca that will see how Ser­no­va’s im­plantable med­ical de­vice works in com­bi­na­tion with cell ther­a­pies.

Per the agree­ment, As­traZeneca will in­ves­ti­gate Ser­no­va’s Cell Pouch Sys­tem as a pos­si­ble plat­form to in­te­grate with ther­a­peu­tic cells.

Ser­no­va said the ex­per­i­men­tal ap­proach could be used to treat pa­tients with in­sulin-de­pen­dent di­a­betes, hy­pothy­roidism and he­mo­phil­ia A. The com­pa­ny did not dis­close what dis­ease cat­e­gories it will work on with As­traZeneca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER